29 56

Cited 0 times in

Cannabidiol for Treating Lennox-Gastaut Syndrome and Dravet Syndrome in Korea

DC FieldValueLanguage
dc.contributor.author강훈철-
dc.contributor.author구청모-
dc.contributor.author김세희-
dc.contributor.author김흥동-
dc.contributor.author이준수-
dc.date.accessioned2021-01-19T08:02:48Z-
dc.date.available2021-01-19T08:02:48Z-
dc.date.issued2020-12-
dc.identifier.issn1011-8934-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/181437-
dc.description.abstractBackground: For the first time in Korea, we aimed to study the efficacy and safety of cannabidiol (CBD), which is emerging as a new alternative in treating epileptic encephalopathies. Methods: This study was conducted retrospectively with patients between the ages of 2-18 years diagnosed with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) were enrolled from March to October 2019, who visited outpatient unit at 3 and 6 months to evaluate medication efficacy and safety based on caregiver reporting. Additional evaluations, such as electroencephalogram and blood tests, were conducted at each period also. CBD was administered orally at a starting dose of 5 mg/kg/day, and was maintained at 10 mg/kg/day. Results: We analyzed 34 patients in the LGS group and 10 patients in the DS group between the ages of 1.2-15.8 years. In the 3-month evaluation, the overall reduction of seizure frequency in the LGS group was 52.9% (>50% reduction in 32.3% of the cases), and 29.4% in the 6-month evaluation (more than 50% reduction in 20.6%). In DS group, the reduction of seizure frequency by more than 50% was 30% and 20% in the 3-month and 6-month evaluation, respectively. Good outcomes were defined as the reduction of seizure frequency by more than 50% and similar results were observed in both LGS and DS groups. Adverse events were reported in 36.3% of total patients of which most common adverse events were gastrointestinal problems. However, no life-threatening adverse event was reported in both LGS and DS during the observation period. Conclusion: In this first Korean study, CBD was safe and tolerable for use and could be expected to potentially reduce the seizure frequency in pediatric patients with LGS or DS.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisher대한의학회(The Korean Academy of Medical Sciences)-
dc.relation.isPartOfJOURNAL OF KOREAN MEDICAL SCIENCE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleCannabidiol for Treating Lennox-Gastaut Syndrome and Dravet Syndrome in Korea-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.department;Dept. of Pediatrics (소아과학교실)-
dc.contributor.googleauthorChung Mo Koo-
dc.contributor.googleauthorSe Hee Kim-
dc.contributor.googleauthorJoon Soo Lee-
dc.contributor.googleauthorByung Joo Park-
dc.contributor.googleauthorHae Kook Lee-
dc.contributor.googleauthorHeung Dong Kim-
dc.contributor.googleauthorHoon Chul Kang-
dc.identifier.doi10.3346/jkms.2020.35.e427-
dc.contributor.localIdA00102-
dc.contributor.localIdA06014-
dc.contributor.localIdA06014-
dc.contributor.localIdA00611-
dc.contributor.localIdA00611-
dc.contributor.localIdA01208-
dc.contributor.localIdA01208-
dc.contributor.localIdA03177-
dc.contributor.localIdA03177-
dc.relation.journalcodeJ01517-
dc.identifier.eissn1598-6357-
dc.identifier.pmid33372424-
dc.subject.keywordCannabidiol-
dc.subject.keywordDravet Syndrome-
dc.subject.keywordLennox Gastaut Syndrome-
dc.contributor.alternativeNameKang, Hoon Chul-
dc.contributor.affiliatedAuthor강훈철-
dc.contributor.affiliatedAuthor구청모-
dc.contributor.affiliatedAuthor구청모-
dc.contributor.affiliatedAuthor김세희-
dc.contributor.affiliatedAuthor김세희-
dc.contributor.affiliatedAuthor김흥동-
dc.contributor.affiliatedAuthor김흥동-
dc.contributor.affiliatedAuthor이준수-
dc.contributor.affiliatedAuthor이준수-
dc.citation.volume35-
dc.citation.number50-
dc.citation.startPagee427-
dc.identifier.bibliographicCitationJOURNAL OF KOREAN MEDICAL SCIENCE, Vol.35(50) : e427, 2020-12-
Appears in Collections:
1. College of Medicine (의과대학) > Others (기타) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.